Cartalax

Buy Cartalax Online

Cartalax is a synthetic tripeptide composed of alanine, glutamic acid, and aspartic acid (Ala-Glu-Asp). It belongs to the short-peptide bioregulator family and is primarily associated with research into connective tissue, joint function, cartilage biology, and age-related tissue changes.

Product Information

Cartalax has been classified within the Khavinson peptide-bioregulator system as a joint- and connective-tissue-associated peptide. Its defined structure is established, but compound-specific biological evidence is considerably more limited than the broader claims often made about it online.

How It Works

The proposed activity of Cartalax is based on the tissue-specific peptide-bioregulator concept, in which short peptides may influence cellular differentiation and gene-expression processes. Direct evidence establishing a specific receptor-mediated mechanism for Cartalax remains limited.

POTENTIAL BENEFITS

1. Joint Research

Cartalax is primarily associated with research into joint and connective-tissue biology. Its proposed tissue-specific activity makes it interesting for investigating cellular processes involved in maintaining joint tissues.

2. Cartilage Research

Cartilage degeneration is closely connected with changes in extracellular matrix production and cellular differentiation. Cartalax has been investigated within the broader short-peptide research field examining how small peptides may influence these processes.

3. Connective-Tissue Research

Cartalax is of interest in research involving connective tissue because the peptide-bioregulator family has been proposed to influence tissue-specific cellular activity. This makes it relevant to studies of age-related structural changes.

4. Cellular Differentiation Research

Short peptides from the Khavinson family have demonstrated tissue-specific effects on differentiation-related markers in experimental models. Cartalax is positioned within this research framework, although direct evidence for Cartalax remains limited.

5. Aging-Related Tissue Research

Cartalax provides a model for investigating whether short regulatory peptides can influence cellular processes associated with tissue aging and regeneration. This remains an area of experimental rather than established clinical research.

Dosage

No established human dosage exists for Cartalax.

Online peptide sources report various research amounts, including approximately 2 mg/day, but these figures are not supported by established human clinical dose-finding studies and should be considered reported research-market information rather than validated dosing.

Side Effects

Human safety data are limited. Potential concerns include:

• Individual sensitivity
• Injection-site reactions where applicable
• Unknown long-term effects
• Unknown medication interactions

References

1. PubChem. Alanyl-glutamyl-aspartic acid (Cartalax). PubChem
2. Khavinson VK, et al. Mechanism of biological activity of short peptides. Research publication

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Please click here to see how purchases actually work on this site.